Danaher Corporation (NYSE:DHR) insider Thomas Patrick Joyce, Jr. sold 9,772 shares of Danaher Corporation stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $81.78, for a total value of $799,154.16. Following the completion of the sale, the insider now directly owns 155,520 shares in the company, valued at approximately $12,718,425.60. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of Danaher Corporation (NYSE DHR) traded down 0.05% on Friday, reaching $80.87. 2,861,306 shares of the company’s stock traded hands. Danaher Corporation has a one year low of $75.71 and a one year high of $88.01. The firm has a market cap of $56.18 billion, a P/E ratio of 25.81 and a beta of 1.03. The company’s 50-day moving average price is $82.32 and its 200 day moving average price is $84.22.
Danaher Corporation (NYSE:DHR) last posted its quarterly earnings data on Thursday, July 20th. The conglomerate reported $0.99 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.02. The firm had revenue of $4.51 billion for the quarter, compared to analysts’ expectations of $4.50 billion. Danaher Corporation had a net margin of 12.63% and a return on equity of 11.15%. The business’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter last year, the company posted $0.90 EPS. On average, equities analysts forecast that Danaher Corporation will post $3.95 EPS for the current fiscal year.
Several analysts have issued reports on the company. Janney Montgomery Scott downgraded Danaher Corporation from a “buy” rating to a “neutral” rating in a research note on Wednesday, June 7th. BidaskClub upgraded Danaher Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Deutsche Bank AG restated a “buy” rating and issued a $97.00 price objective on shares of Danaher Corporation in a report on Wednesday, June 21st. Zacks Investment Research cut Danaher Corporation from a “hold” rating to a “sell” rating in a report on Monday, June 19th. Finally, Credit Suisse Group reiterated a “buy” rating and set a $93.00 price target on shares of Danaher Corporation in a report on Wednesday, May 24th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Danaher Corporation currently has an average rating of “Buy” and an average target price of $91.76.
Several hedge funds have recently bought and sold shares of DHR. GQG Partners LLC bought a new stake in Danaher Corporation during the second quarter valued at $101,000. Peddock Capital Advisors LLC boosted its position in shares of Danaher Corporation by 17.4% in the first quarter. Peddock Capital Advisors LLC now owns 1,224 shares of the conglomerate’s stock worth $105,000 after buying an additional 181 shares during the last quarter. Proficio Capital Partners LLC boosted its position in shares of Danaher Corporation by 92.3% in the first quarter. Proficio Capital Partners LLC now owns 1,246 shares of the conglomerate’s stock worth $105,000 after buying an additional 598 shares during the last quarter. Monetary Management Group Inc. boosted its position in shares of Danaher Corporation by 10.7% in the second quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock worth $131,000 after buying an additional 150 shares during the last quarter. Finally, Acrospire Investment Management LLC boosted its position in shares of Danaher Corporation by 185.5% in the second quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock worth $143,000 after buying an additional 1,100 shares during the last quarter. Hedge funds and other institutional investors own 76.12% of the company’s stock.
About Danaher Corporation
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with our FREE daily email newsletter.